Tolvaptan is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).
Tolvaptan API is still in R&D stage, and the US-DMF is also submitted in schedule.
Tolvaptan is a selective vasopressin V2 receptor antagonist used primarily for hyponatremia. Its core synthesis involves complex organic coupling reactions. The molecular formula is C30H41N5O4 with CAS No. 189657-07-0.
Contraindicated in anuria or hepatic impairment. Strict monitoring of liver enzymes is required due to hepatotoxicity risks. Store at controlled room temperature below 25°C in dry, light-resistant containers.